Ubrogepant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Ubrogepant
Ubrogepant.svg
Clinical data
SynonymsMK-1602
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC29H26F3N5O3
Molar mass549.55 g·mol−1
3D model (JSmol)

Ubrogepant is an experimental drug for the treatment of migraine. It is a small-molecule calcitonin gene-related peptide receptor antagonist.[1][2]

References[edit]

  1. ^ Tfelt-Hansen, P; Olesen, J (April 2011). "Possible Site of Action of CGRP Antagonists in Migraine". Cephalalgia: An International Journal of Headache. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046.
  2. ^ Spreitzer, H (22 May 2018). "Neue Wirkstoffe: Ubrogepant". Österreichische Apotheker-Zeitung (in German) (11/2018).